Ingo G.H. Schmidt‐Wolf
- Oncology top 0.5%
- CAR-T cell therapy research 51
- Cancer Immunotherapy and Biomarkers 24
- Immunology top 0.5%
- Immune Cell Function and Interaction 64
- Immunotherapy and Immune Responses 57
- T-cell and B-cell Immunology 26
- Genetics top 0.5%
- Glioma Diagnosis and Treatment 20
- Cancer Research top 1%
- Hematology top 1%
-
- Lymphoma Diagnosis and Treatment 30
-
- CNS Lymphoma Diagnosis and Treatment 23
- Co-authors
- Gabriele Schmidt‐WolfJanice DutcherGary R. HudesErhan GökmenStephanie LustgartenRobert J. MotzerVladimir LesovoyRobert A. Figlin
- Cited by
- OncologyImmunologyGenetics
- Journals
- New England Journal of Medicine (1 paper)Journal of Clinical Oncology (10 papers)SHILAP Revista de lepidopterología (11 papers)
- Partner nations
- GermanyUnited StatesChina
In The Last Decade
Ingo G.H. Schmidt‐Wolf
241 papers receiving 10.2k citations
Hit Papers
Peers
Comparison fields: 5 of 147
- Oncology 3.9k
- Immunology 2.9k
- Genetics 1.3k
- Cancer Research 1.5k
- Hematology 1.1k
Countries citing papers authored by Ingo G.H. Schmidt‐Wolf
This map shows the geographic impact of Ingo G.H. Schmidt‐Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingo G.H. Schmidt‐Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingo G.H. Schmidt‐Wolf more than expected).
Fields of papers citing papers by Ingo G.H. Schmidt‐Wolf
This network shows the impact of papers produced by Ingo G.H. Schmidt‐Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingo G.H. Schmidt‐Wolf. The network helps show where Ingo G.H. Schmidt‐Wolf may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ingo G.H. Schmidt‐Wolf, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 20 | |
| 2 | 2024 | 29 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 3 | |
| 5 | 2022 | 9 | |
| 6 | 2022 | 6 | |
| 7 | 2021 | 21 | |
| 8 | 2021 | 4 | |
| 9 | 2011 | 12 | |
| 10 | 2010 | 255 | |
| 11 | 2010 | 55 | |
| 12 | Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide | 2009 | 1 |
| 13 | High dose chemotherapy with autologous stem cell transplantation in diffuse large B-cell lymphoma | 2007 | 2 |
| 14 | Minimal size MIDGE vectors improve transgene expression in vivo. | 2007 | 31 |
| 15 | 2006 | 8 | |
| 16 | 2004 | 5 | |
| 17 | 2003 | 109 | |
| 18 | 2002 | 9 | |
| 19 | 2001 | 6 | |
| 20 | 1999 | 28 |
About Ingo G.H. Schmidt‐Wolf
Ingo G.H. Schmidt‐Wolf is a scholar working on Immunology, Oncology and Genetics, having authored 248 papers that have together received 10.4k indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (64 papers), Immunotherapy and Immune Responses (57 papers), CAR-T cell therapy research (51 papers), Lymphoma Diagnosis and Treatment (30 papers), T-cell and B-cell Immunology (26 papers), Cancer Immunotherapy and Biomarkers (24 papers), CNS Lymphoma Diagnosis and Treatment (23 papers) and Glioma Diagnosis and Treatment (20 papers). The work is most often cited by research in Oncology (3.9k citations), Immunology (2.9k citations) and Genetics (1.3k citations). Ingo G.H. Schmidt‐Wolf has collaborated with scholars based in Germany, United States and China. Frequent co-authors include Gabriele Schmidt‐Wolf, Janice Dutcher, Gary R. Hudes, Erhan Gökmen, Stephanie Lustgarten, Robert J. Motzer, Vladimir Lesovoy, Robert A. Figlin, Piotr Tomczak and Anil Kapoor. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.